Acorda Therapeutics (NASDAQ:ACOR) earns a D this week, falling from last week???s grade of C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system.